Clinical trial · Interventional
Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint
Exploratory Evaluation of a Transrectal Scintigraphic Detector (Proxiscan) for Detection of Primary Prostate Cancer Utilizing a Radiotracer Targeting Prostate Specific Membrane Antigen (PMSA)
NCT01394042CI-TRIAL-00005209unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a small study to determine if probe, similar to an ultrasound probe, can detect prostate cancer more specifically than other imaging studies in patients with a positive prostate cancer biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Proxiscan device | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- No intervention
- description
- All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
- interventionNames
- Device: Proxiscan device
Primary outcomes (1)
- measure
- Detection of PSMA antibody (ProstaScint)uptake patterns measured by Proxiscan in comparison with anatomic biopsy reports, conventional SPECT and MRI scans within one month of Proxiscan
- timeFrame
- Within on month of scan and corresponding MRI
- description
- Detection of PSMA antibody (ProstaScint) uptake patterns measured by the new transrectal compact gamma camera (Proxiscan) will be compared to the anatomic biopsy reports along with Magnetic Resonance Imaging (MRI) and conventional ProstaScint (Single Photon Emission Computed Tomography) SPECT imaging results. All imaging and biopsy results performed within one month will be used for this investigation
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Primary prostate cancer proven by sextant prostate biopsy * Transrectal ultrasound (TRUS)-guided prostate biopsy within 6 months of study enrollment * Sufficient time period to complete imaging protocol and 5-7 day safety followup assessment without other therapeutic intervention * In the judgement of principal investigator, patient able to provide informed consent and be compliant with protocol requirements * ECOG status of 0 or 1 Pt \> 18 yrs of age Exclusion Criteria: * Definitive or concomitant therapeutic intervention within the interval of study intervention * Prior pelvic therapeutic radiation * Active malignancy or therapy for malignancy with 6 months other than basal or squamous cell carcinoma of the skin * Pt received radiopharmaceutical which was within 5 half-lives at the time of studying imaging * Known history of human-anti-murine-antibodies or known allergic reaction to previously received murine based products
References
Publications (0)
Data not yet available
No reference posted for this study.